Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-tumor pharmaceutical composition with synergistic effects and application thereof

An anti-tumor drug and a synergistic technology, which is applied in the field of anti-tumor pharmaceutical compositions and pharmaceutical compositions for the treatment of cancer, can solve problems such as the increase of active oxygen, and achieve the effects of reducing side effects, inhibiting growth, and safe clinical use

Active Publication Date: 2019-12-20
SHENYANG PHARMA UNIVERSITY
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(3) Studies have found that CoCl 2 Induced cellular hypoxia leads to an increase in reactive oxygen species

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor pharmaceutical composition with synergistic effects and application thereof
  • Anti-tumor pharmaceutical composition with synergistic effects and application thereof
  • Anti-tumor pharmaceutical composition with synergistic effects and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Embodiment 1: cell activity experiment

[0068] In this study, human non-small cell lung cancer cell line A549 and human breast cancer cell line MCF-7 were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences; HL-60 human acute promyelocytic leukemia was obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences. Place the cells in 5% CO 2 , 95% air, saturated humidity and 37°C, cultured in the corresponding appropriate culture medium, and added 10% newborn calf serum. In each experiment, cells were seeded at a density of 5 × 10 4 / mL.

[0069] In a 96-well culture plate, 90 μL of cell suspension was inoculated in each well, and the total number of cells was 4500. Set up a zero-adjustment group, a control group and an experimental group, and 6 duplicate wells. 10 μL of drug dilution medium was added to the zero-adjustment group and the experimental group, and 10 μL of corresponding concentration of drug was added to the experimental gr...

Embodiment 2

[0085] Example 2: detection of active oxygen levels

[0086] A549 and MCF-7 cells in good growth state and in logarithmic growth phase were inoculated into cell culture flasks. After adhering to the wall, add various concentrations of drugs and combination drugs, and incubate for 48 hours. According to the ratio of 1:1000, use serum-free DMEM medium to dilute the ROS fluorescent probe DCFH-DA, and prepare 10 μmol L -1 The DCFH-DA. After the cells were collected by trypsinization, the cells were washed three times with PBS and 10 μmol L -1 The DCFH-DA detection solution was used to resuspend the cells in the centrifuge tube, so that the concentration of the cell suspension was 10 6 individual / mL. Place the centrifuge tube in an incubator and incubate for 30 minutes in the dark, and shake the centrifuge tube upside down every 5 minutes to mix the suspension to make the probe fully contact with the cells. After incubation, centrifuge, suck out the DCFH-DA detection solution ...

Embodiment 3

[0088] Example 3: Detection of Mitochondrial Membrane Potential

[0089] A549 and MCF-7 cells in good growth state and in logarithmic growth phase were inoculated into cell culture flasks. After adhering to the wall, add various concentrations of drugs and combination drugs, and incubate for 48 hours. Use DMSO to dissolve the solid powder of the fluorescent dye Rhodamine 123, and make a final preparation of 5 mg·mL -1 Rhodamine 123 solution. After 48 hours, digest the cells with trypsin to collect the cells, wash the cells with PBS 3 times, add 50 μL of rhodamine 123 solution to the cell suspension, place in the incubator and incubate in the dark for 30 minutes, shake the centrifuge tube upside down every 5 minutes, mix and suspend solution to fully contact the dye with the cells. Centrifuge after incubation, suck out the rhodamine 123 solution in the centrifuge tube, and wash the cells with PBS 3 times to completely remove residual dye. Finally, the cells were fixed with ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicines, and relates to a pharmaceutical composition capable of treating cancers; and more specifically, the invention discloses an anti-tumor pharmaceutical composition with synergistic effects and application thereof. By synergistic effects between drugs, dosages of single drugs in the anti-tumor pharmaceutical composition with the synergistic effects are reduced, so that strong toxic effects of the drugs on cells are overcome; and apoptosis of solid tumor cells is induced by increasing active oxygen levels in the cells. The anti-tumor pharmaceutical composition with the synergistic effects disclosed by the invention consists of arsenic trioxide and cobalt salts, wherein a mole ratio of the arsenic trioxide to the cobalt saltsis (1 to 1) to (1 to 10), and preferably (1 to 2) to (1 to 5). The cobalt salts are cobalt acetate, cobalt chloride, cobalt phosphate, cobalt silicate, cobalt succinate, cobalt fumarate and cobalt sulfate. The anti-tumor pharmaceutical composition with the synergistic effects is used for synergistically inhibiting tumor cell growth and promoting tumor cell apoptosis.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a pharmaceutical composition for treating cancer, in particular, a synergistic antitumor pharmaceutical composition and its application. The pharmaceutical composition reduces the dosage of a single drug through the synergistic effect of the drugs, and overcomes the strong toxic effect of the drug on cells. Induces tumor cell apoptosis in solid tumors by increasing intracellular reactive oxygen species levels. Background technique [0002] Arsenic and various other forms of arsenic have been used in ancient Chinese medicine for more than 2,000 years for ailments ranging from syphilis to cancer. Although it has been labeled as a potential "poison," that doesn't overshadow its beneficial healing properties. Arsenic, especially arsenic trioxide (As 2 o 3 , ATO), demonstrated ability in the treatment of acute promyelocytic leukemia (APL), has fundamentally changed the perceptio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/36A61K33/24A61K9/127A61P35/00
CPCA61K33/36A61K33/24A61K9/1278A61P35/00A61K2300/00
Inventor 邓意辉王绍宁王存杨傅凭平宋艳志刘欣荣
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products